25947-18-6

Usage

Uses

Used in Pharmaceutical Synthesis:
Phthalazine hydrazide is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its chemical reactivity and structural features make it a valuable component in the development of new drugs with diverse therapeutic applications.
Used in Anticancer Research:
Phthalazine hydrazide has been studied for its potential as an anticancer agent, particularly due to its ability to inhibit the proliferation of cancer cells. Its mechanism of action and selectivity towards cancer cells are of interest to researchers seeking novel and effective treatments for various types of cancer.
Used in Anti-Inflammatory Applications:
In addition to its anticancer properties, phthalazine hydrazide has also shown potential as an anti-inflammatory agent. Its ability to modulate inflammatory pathways and reduce inflammation may make it a useful compound in the development of treatments for inflammatory diseases.
Used in Medicinal Chemistry Research:
The unique structure and properties of phthalazine hydrazide make it a valuable subject for further research in the field of medicinal chemistry. Its potential applications in drug discovery and development, as well as its mechanistic insights, contribute to the advancement of knowledge in this scientific domain.

InChI:InChI=1/C10H10N4O2/c11-12-9(15)5-8-6-3-1-2-4-7(6)10(16)14-13-8/h1-4H,5,11H2,(H,12,15)(H,14,16)

Upstream product

• 85-44-9 phthalic anhydride 
• 57691-07-3 ethyl [(E)-3-oxo-1,3-dihydroisobenzofuran-1-ylidene]acetate 
• 25947-11-9 1,2-Dihydro-1-oxophthalazin-4-ylacetic acid 
• 13141-32-7 ethyl 2-(3-oxo-1,3-dihydro-1-isobenzofuranyliden)acetate 

Relevant academic research and scientific papers

Rational modification, synthesis and biological evaluation of N-substituted phthalazinone derivatives designed to target interleukine-15 protein

Interleukin (IL)-15 is a pleiotropic cytokine structurally close to IL-2 and sharing with the IL-2Rβ and γc receptor (R) subunits. IL-15 plays important roles in innate and adaptative immunity, supporting the activation and proliferation of NK, NK-T, and CD8+ T cells. Over-expression of IL-15 has been shown to participate to the development of inflammatory and autoimmune diseases and diverse T cell malignancies. This study is in continuity of our previous work through which a family of small-molecule inhibitors impeding IL-15/IL-2Rβ interaction with sub-micromolar activity has been identified using pharmacophore-based virtual screening and hit optimization methods. With the aim to improve the efficacy and selectivity of our lead inhibitor, specific modifications have been introduced on the basis of optimized SAR and modelisation. The new series of compounds generated have been evaluated for their capacity to inhibit the proliferation as well as the down-stream signaling of IL-15-dependent cells and to bind to IL-15.

Discovery of thiazolyl-phthalazinone acetamides as potent glucose uptake activators via high-throughput screening

With the aim to discover orally active small molecules that stimulate glucose uptake, high throughput screening of a library of 5000 drug-like compounds was conducted in differentiated skeletal muscle cells in presence of insulin. N-Substituted phthalazinone acetamide was identified as a potential glucose uptake modulator. Several novel derivatives were synthesized to establish structure activity relationships. Identified lead thiazolyl- phthalazinone acetamide (7114863) increased glucose uptake (EC50 of 0.07 ± 0.02 μM) in differentiated skeletal muscle cells in presence of insulin. Furthermore, 7114863 was superior to rosiglitazone under similar experimental conditions without inducing PPAR-γ agonist activity thus making it a very interesting scaffold.